Krystal Biotech, Inc. KRYS Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $417.3M+7.2% | $389.13M+4.3% | $373.16M+3.9% | $359.21M+7.7% | $333.45M+14.8% | ||
| $59.12M+1.9% | $58.05M+2.2% | $56.78M+1.9% | $55.71M-2.1% | $56.88M+6.2% | ||
| $155.2M+5.7% | $146.83M+7.4% | $136.67M+7.0% | $127.77M+6.3% | $120.23M+5.8% | ||
| $238.66M+4.7% | $227.93M+6.1% | $214.86M-2.2% | $219.8M-2.2% | $224.78M0.0% | ||
| $238.66M+4.7% | $227.93M+6.1% | $214.86M-2.2% | $219.8M-2.2% | $224.78M0.0% | ||
| $178.64M+10.8% | $161.2M+1.8% | $158.31M+13.6% | $139.41M+28.3% | $108.67M+65.3% | ||
| 42.8%+1.4pp | 41.4%-1.0pp | 42.4%+3.6pp | 38.8%+6.2pp | 32.6%+10.0pp | ||
| $28.68M+1.4% | $28.27M-1.3% | $28.64M-2.4% | $29.35M0.0% | $29.36M-0.9% | ||
| $207.32M+9.4% | $189.47M+1.3% | $186.95M+10.8% | $168.75M+22.3% | $138.02M+44.7% | ||
| -$17.72M-15.3% | -$15.36M-28.4% | -$11.96M-154% | $22.03M+56.6% | $14.06M+127% | ||
| $225.03M+9.9% | $204.83M+3.0% | $198.91M+35.6% | $146.73M+18.4% | $123.96M+39.0% | ||
| 53.9%+1.3pp | 52.6%-0.7pp | 53.3%+12.5pp | 40.8%+3.7pp | 37.2%+6.5pp | ||
| $7.48+9.2% | $6.85+2.5% | $6.68+35.5% | $4.93+18.2% | $4.17+39.0% | ||
| $7.75+9.5% | $7.08+2.6% | $6.90+35.0% | $5.11+18.3% | $4.32+38.9% | ||
| 120M+0.5% | 119.4M+0.2% | 119.2M-0.1% | 119.3M+0.1% | 119.2M+0.5% | ||
| 116.1M+0.4% | 115.6M+0.3% | 115.3M+0.2% | 115M+0.3% | 114.7M+0.5% | ||
| $24.34M+5.6% | $23.05M+7.7% | $21.41M-10.2% | $23.83M+5.1% | $22.67M+13.0% | ||
| —— | $0+100% | -$9.38M+50.0% | -$18.75M+33.3% | -$28.13M+25.0% | ||
| $28.68M+1.4% | $28.27M-1.3% | $28.64M-2.4% | $29.35M0.0% | $29.36M-0.9% | ||
| $223.02M+8.2% | $206.16M+3.9% | $198.5M+33.7% | $148.52M+19.1% | $124.65M+41.1% | ||
| $5.78M+2.0% | $5.67M+3.6% | $5.47M+1.9% | $5.37M-8.5% | $5.87M-0.3% | ||
| —— | —— | -$310K-136% | $873K+12.1% | $779K+277% | ||
| $417.3M+7.2% | $389.13M+4.3% | $373.16M+3.9% | $359.21M+7.7% | $333.45M+14.8% | ||
| $178.64M+10.8% | $161.2M+1.8% | $158.31M+13.6% | $139.41M+28.3% | $108.67M+65.3% | ||
| $184.42M+10.5% | $166.88M+1.9% | $163.78M+13.1% | $144.78M+26.4% | $114.54M+59.9% | ||
| $184.42M+10.5% | $166.88M+1.9% | $163.78M+13.1% | $144.78M+26.4% | $114.54M+59.9% | ||
| 44.2%+1.3pp | 42.9%-1.0pp | 43.9%+3.6pp | 40.3%+6.0pp | 34.3%+9.7pp | ||
| $178.64M+10.8% | $161.2M+1.8% | $158.31M+13.6% | $139.41M+28.3% | $108.67M+65.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Krystal Biotech, Inc.'s revenue?
- Krystal Biotech, Inc. (KRYS) generated $417.3M in revenue over the trailing twelve months, up 25.1% year over year.
- Is Krystal Biotech, Inc. profitable?
- Krystal Biotech, Inc. reported $225.0M in net income over the trailing twelve months, a 53.9% net margin.
- What is Krystal Biotech, Inc.'s earnings per share?
- Krystal Biotech, Inc.'s diluted EPS over the trailing twelve months is $7.48.
- Where does Krystal Biotech, Inc.'s income statement data come from?
- Every line is extracted from Krystal Biotech, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
